{"product_id":"cagrisema-12-pen-bodypharm","title":"Cagrisema 12 Pen - BodyPharm","description":"\u003cp\u003e\u003cspan\u003eCagriSema\u003c\/span\u003e is a next-generation injectable weight-management medication being developed. It combines two different appetite-regulating medicines:\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eCagrilintide\u003c\/span\u003e – a long-acting amylin analogue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eSemaglutide\u003c\/span\u003e – a GLP-1 receptor agonist, the active ingredient in Ozempic and Wegovy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eThe idea is to target two complementary appetite pathways rather than relying on GLP-1 activity alone.\u003c\/p\u003e\n\u003ch2\u003eHow does it work?\u003c\/h2\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cstrong\u003eCagrilintide — the amylin pathway\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMimics amylin, a hormone naturally released alongside insulin after eating. It helps regulate appetite, increase fullness and reduce food intake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cstrong\u003eSemaglutide — the GLP-1 pathway\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eActivates GLP-1 receptors, helping regulate appetite, slow gastric emptying and improve glucose-dependent insulin secretion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003eTogether:\u003c\/span\u003e The combination is designed to increase satiety, reduce hunger and help people consume fewer calories.\u003c\/p\u003e\n\u003ch2\u003eHow effective is it?\u003c\/h2\u003e\n\u003cp\u003eThe clinical results have been impressive.\u003c\/p\u003e\n\u003cp\u003eIn the Phase 3 REDEFINE 1 trial, CagriSema achieved approximately \u003cspan\u003e22.7% average weight loss over 68 weeks\u003c\/span\u003e under the trial's efficacy estimand. Results were lower when accounting for treatment discontinuation and other real-world factors. \u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cspan\u003eNovo Nordisk U.S.\u003c\/span\u003e\u003cspan\u003e+1\u003c\/span\u003e\n\u003c\/div\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eAn important comparison:\u003c\/p\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003e\n\u003cp\u003eMedication\u003c\/p\u003e\n\u003c\/th\u003e\n\u003cth\u003e\n\u003cp\u003eMain mechanism\u003c\/p\u003e\n\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eSemaglutide\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eGLP-1\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eTirzepatide\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eGIP + GLP-1\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eCagriSema\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eAmylin + GLP-1\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003eInterestingly, in the 2026 REDEFINE 4 head-to-head trial, CagriSema achieved 23% weight loss over 84 weeks but did not meet its primary endpoint of demonstrating non-inferiority to tirzepatide 15 mg. \u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch2\u003eIs it approved yet?\u003c\/h2\u003e\n\u003cdiv\u003eRegulatory review ongoing\u003c\/div\u003e\n\u003cp\u003eAs of 9 November 2026:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eSubmitted its US FDA application in December 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eAn FDA decision is expected in Q4 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eIt remains an investigational treatment rather than an established, generally approved weight-loss product. \u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eWhat about side effects?\u003c\/h2\u003e\n\u003cp\u003eBecause it includes semaglutide and an amylin analogue, gastrointestinal side effects are important considerations:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eNausea\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eVomiting\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eConstipation\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eDiarrhoea\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eAbdominal discomfort\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eReduced appetite\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThere are also concerns around dehydration, gallbladder complications and maintaining adequate nutrition during substantial weight loss.\u003c\/p\u003e\n\u003cp\u003eIt should not simply be added to an existing semaglutide or tirzepatide regimen.\u003c\/p\u003e\n\u003ch2\u003eWhy is it interesting?\u003c\/h2\u003e\n\u003cp\u003eI think the most interesting aspect of CagriSema is its dual-hormone approach. Rather than simply increasing GLP-1 activity, it adds an entirely different appetite-regulating pathway.\u003c\/p\u003e\n\u003cp\u003eFor the LIFE.OS research side, it is worth understanding as part of the next generation of metabolic therapies, alongside tirzepatide and emerging amylin-based treatments.\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOne distinction worth exploring:\u003c\/span\u003e CagriSema is not the same as combining cagrilintide and semaglutide independently. The clinical product is a specifically developed fixed-dose combination with its own formulation, dosing and clinical-trial evidence. I would be cautious about research-vial combinations being marketed as equivalent.\u003c\/p\u003e","brand":"LIFE.OS","offers":[{"title":"Default Title","offer_id":54885565169982,"sku":null,"price":1700.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0970\/9826\/8990\/files\/Cagrisema12_1.png?v=1794220085","url":"https:\/\/life-os.co.za\/products\/cagrisema-12-pen-bodypharm","provider":"LIFE.OS","version":"1.0","type":"link"}